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Chronic  hepatitis  C  is  a  systemic  disease  inducing  metabolic  alterations  leading  to  extrahepatic  con-
sequences.  In  particular,  hepatitis  C virus (HCV)  infection  seems  to increase  the  risk  of incident  type
2 diabetes  mellitus  in  predisposed  individuals,  independently  of liver  disease  stage.  The  mechanisms
through  which  hepatitis  C induces  T2DM  involve  direct  viral  effects,  insulin  resistance,  pro-inﬂammatory
cytokines  and  other  immune-mediated  processes.  Many  studies  have  reported  the  clinical  consequences
of  type  2 diabetes  mellitus  on  hepatitis  C outcome,  but very  few  studies  have addressed  the issue  of
microangiopathic  complications  among  patients  with  hepatitis  C only,  who  develop  type  2  diabetes  mel-
litus.  Moreover,  clinical  trials  in HCV-positive  patients  have  reported  improvement  in glucose metabolism
after  antiviral  treatment;  recent  studies  have  suggested  that  this  metabolic  amelioration  might  have  ansulin resistance
nterferon
icroangiopathy
ibavirin
clinical  impact  on  type 2 diabetes  mellitus-related  complications.  These  observations  raise  the  question
as  to whether  the  HCV  eradication  may  also have  an  impact  on the  future  morbidity  and  mortality  due  to
type  2 diabetes  mellitus.  The  scope  of  this  review  is  to summarise  the  current  evidence  linking  success-
ful  antiviral  treatment  and the  prevention  of  type  2  diabetes  mellitus  and  its  complications  in hepatitis
C-infected  patients.
©  2015  Editrice  Gastroenterologica  Italiana  S.r.l.  Published  by Elsevier  Ltd.  All  rights  reserved.. Introduction
Infection with hepatitis C virus (HCV) is a major cause of chronic
epatitis, cirrhosis and hepatocellular carcinoma worldwide [1,2].
hronic HCV infection has been associated with several extrahep-
tic complications, such as essential mixed cryoglobulinaemia, por-
hyria cutanea tarda, glomerulonephritis, autoimmune thyroiditis,
ialadenitis, and cardiomyopathy [3–7]. The available data suggest
hat patients with chronic hepatitis C (CHC) might be characterised
y a high prevalence of metabolic derangements [8–10], some of
hich appear to be profoundly modiﬁed following viral eradication
8,11,12]. Growing evidence shows that HCV increases the risk of
ncident type 2 diabetes mellitus (T2DM) in predisposed individu-
ls [12–16]. The mechanism whereby HCV induces T2DM is insulin
esistance (IR) [17]. HCV was shown to impair the hepatocyte
nsulin signalling pathway by several mechanisms [18], including
∗ Corresponding author at: Gastroenterology Unit, San Luigi Gonzaga Hospi-
al,  Regione Gonzole 10, 10100 Orbassano, Torino, Italy. Tel.: +39 011 9026600;
ax:  +39 011 9026799.
E-mail address: g.saracco@tin.it (G. Saracco).
ttp://dx.doi.org/10.1016/j.dld.2015.10.016
590-8658/© 2015 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. Allthe stimulus to the production of tumour necrosis factor- (TNF-),
the serine phosphorylation of the insulin receptors (IRS), the over-
expression of the suppressor of cytokines (SOC-3) [19,20] and the
induction of SOC-7 [21]. However, although HCV infects mainly the
liver, whole body insulin sensitivity is also impaired in CHC patients
without metabolic syndrome, as shown by recent studies [22,23].
This suggests that the infected hepatocytes might produce medi-
ators that induce endocrine effects at extrahepatic sites, such as
the skeletal muscle (Fig. 1). The virus-induced metabolic derange-
ments may  interact with host-related genetic and environmental
factors, aggravating insulin resistance and possibly leading to the
development of T2DM. An imbalance in the adipocytokine proﬁle
and the presence of liver steatosis/steatohepatitis could contribute
to this scenario [24–32]. Once it has occurred, T2DM contributes to
the acceleration of the progression of liver damage, to an increase
in the risk of hepatocellular carcinoma (HCC) development and to
impairment of the response to antiviral therapy. Finally, a possible
direct viral effect, together with a systemic chronic inﬂammatory
state and the interaction with metabolic derangements, could play
a role in the development of cardiovascular disease.
T2DM seems not only to accelerate the course of CHC [33–39],
but also to inﬂuence the response to antiviral therapy [40–45].
 rights reserved.
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oig. 1. Tentative explanation of the pathogenesis of hepatitis C virus-induced type 2
,  tumour necrosis factor-; IL-6, interleukin-6; IL-18, interleukin-18; IL-28B, interl
rotein 3; HCC, hepatocellular carcinoma; CVD, cardiovascular disease.
mportantly, T2DM occurring in the course of CHC greatly increases
he risk of HCC [46–50], even in patients without cirrhosis and after
he eradication of HCV infection [51].
If HCV is directly involved in the development of IR and T2DM,
t is reasonable to hypothesise that its clearance might result in
 parallel decrease in the risk of T2DM incidence. Conversely, a
uccessful eradication of HCV would improve clinical outcomes in
atients with established T2DM.
The aim of this review is to carry out an extensive examination
f data on the response of HCV-induced IR to successful antiviral
reatment to evaluate its efﬁcacy in preventing the development
f T2DM in CHC patients and in improving the clinical outcomes of
iabetic patients.
To analyse the pertinent data, we searched for published stud-
es in English in selected databases, including PubMed, ISI Web
f Science, Google Scholar, and Scopus, covering the period from
998 to December 2014. The literature search was performed
sing combinations of selected key- and text-words includ-
ng “insulin resistance”, “diabetes”, “type 2 diabetes mellitus”,
T2DM”, “microangiopathy”, “diabetic microangiopathy”, “hepati-
is”, “chronic hepatitis C”, “hepatitis C virus”, “HCV”, “risk factor”,
meta-analysis”, “systematic review”, “review”.
. Impact of SVR on T2DM incidence
Studies addressing the clinical impact of sustained virological
esponse (SVR) on IR or T2DM incidence are reported in Table 1.
everal studies [41,52–57] reported a reduction in the number of
atients with IR treated with interferon (IFN)-based plus ribavirin
RBV) therapies after achievement of SVR. Aghemo et al. [58] con-
rmed the persistence of this beneﬁcial effect in cured patients
uring a prolonged follow-up, preventing the potential bias repre-
ented by weight loss during IFN/RBV treatment. The mechanism
hrough which antiviral therapy ameliorates IR has not been fully
stablished, but it is most likely mediated via viral clearance, rather
han a direct pharmacological effect of IFN/RBV. Anyway, the above-
entioned studies provided the proof-of-concept on the possibility
f obtaining a signiﬁcant decrease in IR incidence in patients withtes mellitus and related clinical outcomes. SVR, sustained virological response; TNF-
-28B; IR, insulin resistance; PNPLA3, patatin-like phospholipase domain-containing
SVR; however, this epidemiological ﬁnding did not by default trans-
late into any deﬁnite clinical beneﬁt for patients; in fact, the really
strong endpoint is the reduction in the incidence of T2DM and its
complications. This issue was  addressed by a few studies [52,55,59]
that reported a signiﬁcantly reduced incidence of T2DM among sus-
tained responders. Only one study [60] failed to show a statistically
signiﬁcant lower incidence of T2DM in eradicated patients com-
pared with non-responders. The discrepancy may be explained by
the different baseline features (low number of cirrhotics, predispo-
sition to hepatogenous T2DM) of the patients and by the weight
increase observed among sustained responders included in the
Italian study. T2DM occurrence is associated with a genetic predis-
position, but it is also inﬂuenced by lifestyle-related aspects, such as
dietary habits and physical activity. For this reason, epidemiologi-
cal variations concerning T2DM in CHC patients should always take
into account important demographic and clinical features such as
family history, age, sex, obesity, smoking habit and physical activ-
ity. In other words, how much is the virus and how much is lifestyle
(and genetics) responsible for inducing T2DM? Does viral eradica-
tion per se afford protection from T2DM development, or do the
above-mentioned factors play a pivotal role in disease occurrence?
According to Arase et al. [59], viral eradication induced a
two-thirds reduction in the risk of incident T2DM, independent
of age, presence of cirrhosis and of pre-diabetes before therapy.
Unfortunately, the authors did not report data regarding important
baseline variables such as family history for T2DM, smoking habit,
physical activity and IR. Moreover, the retrospective design of
the study did not provide us with results on BMI  at the end of
follow-up and, last but not least, patients included in this study
showed pre-therapy characteristics (low BMI, high rate of geno-
type 2, high antiviral efﬁcacy) that are infrequent in most Western
countries. Caution is thus recommended before extrapolating the
results to non-Asian populations. On the other hand, analysis of
Western series [52,55] led to similar conclusions; in particular,
Romero-Gómez et al. [55] showed that eradication of HCV reduced
the incidence of T2DM by half in a large cohort of CHC patients
during the post-treatment follow-up. Interestingly, the authors
reported older age, abnormal glucose values and steatosis, all
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Table  1
Reported impact of sustained virological response on insulin resistance or type 2 diabetes mellitus incidence in patients treated for hepatitis C.
Author, year (ref) Type of study Genotype IR improvement DM incidence
reduction
Comments
Romero-Gomez, 2005 [41] Prospective 1–4 Yes – No follow-up data
Simò,  2006 [52] Retrospective 1–4 Probable Yes No measurement of insulin resistance
Kawaguchi, 2007 [53] Prospective 1,2 Yes – – Genotype 1–2 only
–  Small sample size
– Baseline IR not considered in the
analysis
Romero-Gomez, 2008 [55] Prospective 1–4 Probable Yes No measurement of insulin resistance
Giordanino, 2008 [60] Retrospective 1–4 n.a. No – Small sample size
– Low number of cirrothics
Kawaguchi, 2009 [54] Prospective 1,2 Yes – – Genotype 1–2 only
–  Small sample size
Arase,  2009 [59] Retrospective 1,2 – Yes – No data on confounding variables
(family history, smoking habits, BMI at
f.u.)
Delgado-Borrego, 2010 [56] Prospective n.a. Yes – – Genotype 3 excluded
– No data regarding SVR
Aghemo, 2012 [58] Prospective 1–4 Yes – Small sample size
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R, insulin resistance; DM,  diabetes mellitus; BMI, body mass index; SVR, sustained
actors related to IR, to be independent predictors of non-response.
t is reasonable to think that patients who did not respond to
herapy were those more prone to developing T2DM, even though
he incidence of T2DM remained statistically different even when
orrected by multivariate analysis considering variables strongly
elated to the risk of developing T2DM.
In conclusion, the incidence of IR and T2DM appears to be
educed in CHC patients who obtain SVR after therapy, but the
xtent of this reduction is questionable and probably depends on
he genetic, demographic, clinical, histological and lifestyle char-
cteristics of the patients, owing to the multifactorial aetiology of
2DM. For this reason, the eradication of HCV in patients with pre-
isposing factors for T2DM should not preclude proper counselling
n diet and physical activity.
. Hepatogenous vs. HCV-related T2DM
T2DM, which develops as a complication of advanced liver dis-
ase, is a well-known condition deﬁned as “hepatogenous diabetes”
61]. The pathogenesis of hepatogenous T2DM is not yet fully
nderstood. Generally, IR in the peripheral tissues, secondary to
uscle depletion and cytokine production, and in the liver because
f liver damage, is the main metabolic disturbance [62,63]. Another
mportant factor is hyperinsulinaemia induced by reduced insulin
xtraction by the cirrhotic liver due to altered function or por-
osystemic shunts, along with raised levels of counter regulatory
ormones and free fatty acids [62]. However, the aetiology of liver
isease seems important: HCV in particular plays a direct role in
nducing IR and T2DM by interfering with glucose metabolism inde-
endently of age and stage of liver disease [64,65], while other
etiologies of liver disease, such as alcohol and hepatitis B virus
HBV), require the presence of cirrhosis. This statement has been
ecently revisited by Ruhl et al. [66], who showed that T2DM is asso-
iated with liver enzyme elevation, rather than with HCV infection
er se, conﬁrming the previous results of an Italian study that did
ot show a different prevalence of T2DM among cirrhotics with
CV, HBV infection or alcohol abuse [67]. According to Ruhl et al.
66], other metabolic and histological factors play a crucial role in
he association between HCV and T2DM. However, many studies
15,68,69] indicate that HCV, rather than HBV infection, is speciﬁ-
ally associated with T2DM, suggesting that HCV probably impairs
nsulin sensitivity independent of chronic hepatitis, although, of
ourse, hepatic ﬁbrosis increases the risk of T2DM. HCV infection
as independently associated with an increased risk of T2DM and– Genotype 4 excluded
ogical response; n.a, not available.
IR in the US population over a decade ago, but assessment of the
later NHANES cycles has shown that this relationship may  have
been weakened by the rapid rise of other risk factors for T2DM,
speciﬁcally obesity [70]. Future studies should probably take into
account, and control carefully for, the link between cirrhosis (a
major factor in T2DM) when assessing HCV infection in clinic-based
studies [71].
The distinction between hepatogenous T2DM and “classical”
T2DM is not trivial; in fact, according to some studies [72–75],
hepatogenous T2DM is considered clinically different from the
“classical” T2DM, because it is less frequently associated with
microangiopathy. However, this conclusion is mainly derived from
the results of cross-sectional studies including patients with dis-
similar aetiologies of liver cirrhosis (Table 2).
Marchesini et al. [72] showed a lower prevalence of micro-
and peripheral macroangiopathy in diabetic cirrhotics compared
with non-cirrhotic diabetic patients; however, the study was cross-
sectional, the aetiology of cirrhosis was  heterogeneous (HBV,
HCV, alcohol, primary biliary cirrhosis, Wilson’s disease, alpha1-
antitrypsin deﬁciency, haemochromatosis) and the duration of
diabetes was  signiﬁcantly longer in diabetic patients without cir-
rhosis. Holstein et al. [73] reported an overall rate of 8% retinal
complications in 52 patients with cirrhosis and T2DM; no T2DM-
related complications were observed among 20 patients with
newly diagnosed T2DM during follow-up. However, only 19% of
patients were HCV-positive and the follow-up period was short
(3.9 years). Kuriyama et al. [74] showed a signiﬁcantly lower
incidence of microangiopathy among diabetics with chronic liver
disease (mainly HCV-positive) compared with a matched group
of diabetic patients without liver disease. The main criticisms are
the cross-sectional study design and the fact that the duration
of diabetic disease was not reported. In contrast to the above-
mentioned studies, a recent study [75] reported a signiﬁcantly
higher prevalence of T2DM complications among HCV-positive dia-
betics compared with HCV-negative diabetics; however, no data
regarding baseline liver histology, methods of assessing microan-
giopathy/macroangiopathy and duration of T2DM were described.
The duration of diabetic disease is crucial in determining the real
incidence of T2DM-related complications; to date, only one study
[76] has recruited patients with only newly diagnosed T2DM with-
out baseline micro-/macroangiopathy. Coppo et al. [76] compared
the occurrence of diabetic complications in a CHC cohort with
that of a similar control group of new-onset T2DM, HCV-negative
patients without baseline microangiopathy, comparable for age,
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Table 2
Reported risk of microangiopathic complications in hepatitis C virus-infected diabetic patients.
Author, year (ref) Type of study
(country)
Follow-up
(years)
Study subjects
(n)
Genotype Risk of microangiopathy Comments
Marchesini 1999
[53]
Cross-sectional
(Italy)
– 66 HCV pos
56 HCV neg
All cirrhotics
N/A Lower prevalence of
retinopathy in cirrhotic
diabetics than in non-cirrhotic
diabetics (17% vs 48%)
– Cross- sectional design
– Heterogeneous aetiology of
cirrhosis
– Longer duration of diabetes
in non-cirrhotic diabetics than
in  cirrhotic diabetics (10.1 vs
5.9 years; p < 0.01)
Holstein 2002 [54] Prospective
(Germany)
3.9 10 HCV pos
42 HCV neg
All cirrhotics
N/A Reduced incidence of
retinopathy: 8% of all diabetics
(3/37), 0% (0/20) of newly
diagnosed diabetics
– Only 19% HCV pos
– Short follow-up period
– Small sample size
Kuriyama 2007
[55]
Cross-sectional
(Japan)
– 178 HCV pos
(47% cirrhotics)
51 HCV neg (41%
cirrhotics)
N/A Lower prevalence of
microangiopathy in diabetics
with CLD than in diabetics
without CLD (30% vs 65%;
p < 0.001)
– Cross-sectional design
– Duration of diabetes not
reported
Chehadeh 2011
[56]
Case/control
(Kuwait)
– 24 HCV pos
414 HCV neg
All non-cirrhotics
8% gen1
92% gen 4
Increased prevalence of
micro/macroangiopathy in
HCV pos than in HCV neg
diabetics (96 vs 73%; p = 0.014).
HCV viraemia signiﬁcantly
associated with increased risk
of diabetes-related
complications
(OR 23.65, CI 95% 2.36–236.64;
p = 0.007)
– Lack of histological
evaluation
– Methods to assess
micro/macroangiopathy not
reported
–  Duration of diabetes not
reported
Coppo  2015 [57] Retrospective
(Italy)
7.2 54 HCV pos
(62.9% cirrhotics)
119 HCV neg
(2.52% cirrhotics)
N/A Similar incidence of
microangiopathy in HCV pos
and in HCV neg (24.1% vs
31.1%; p = ns).
No signiﬁcant association
between HCV pos and risk of
diabetes-related complications
(HR 0.74, 95% CI 0.33–1.7;
– Retrospective study
– Small sample size
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2DM duration and length of follow-up. After a 7-year follow-
p, the authors did not ﬁnd any meaningful difference in the
ncidence of both microangiopathic and macroangiopathic com-
lications between patients with newly diagnosed T2DM with or
ithout CHC. Even in this study, some methodological limitations
the retrospective nature, the small number of patients recruited)
hould be taken into consideration when interpreting the results.
To explain the discrepancy between these studies, we  think
hat a reduced life expectancy due to complications of liver dis-
ase among patients with HCV-cirrhosis and T2DM at least partly
ccounts for the lower number of diabetes-related complications
bserved in HCV-positive compared with HCV-negative diabetics
n a series with a high rate of cirrhosis. When cohorts of diabetic
atients (with and without CHC) well matched for baseline demo-
raphic features, duration and therapeutic control of T2DM disease
re prospectively considered, the incidence of microangiopathic
omplications is not different from that observed in patients in
hom viral eradication is not achieved.
. Hepatic steatosis and diabetes: HCV infection vs. NAFLD
In general, hepatic steatosis is considered to be an important
isk factor for T2DM. However, it is crucial to disentangle the rel-
tive roles of HCV infection and NAFLD in the onset of fatty liver
nd the impact of virus-related vs. NAFLD-related steatosis in the
evelopment of glucose intolerance. Given the high prevalence
f both NAFLD and CHC in the general population, the chances
f interactions between these two conditions are signiﬁcant and
linically relevant, not only because of the potential synergism
n liver disease severity, but also because of their interactions onp = 0.49)
metabolism. The association between HCV and steatosis is well-
known and both host and viral factors concur with it [10,77]. After
the common causes of fatty liver, including alcohol abuse and over-
weight/obesity, have been excluded, steatosis occurs in about 40%
of chronic hepatitis C cases [78]. Genotype 3 HCV directly causes
steatosis through several mechanisms, including the inhibition of
triglyceride output from the liver [79]. In genotype 3 CHC, the sever-
ity of steatosis correlates with the level of HCV replication and
decreases upon successful treatment with antivirals [80,81]. In con-
trast, in most patients with genotype non-3, steatosis correlates
with metabolic variables, such as BMI, and tends to persist even
in the case of SVR [81,82]. CHC patients with the highest degrees
of viral steatosis (e.g. infected with genotype 3) do not necessarily
present with the highest levels of IR, and vice versa. HOMA-IR score
levels are higher in patients with genotypes 1 and 4, while patients
with genotype 3, which displays the highest degree of steatosis, are
those in whom HOMA-IR levels are the lowest [35,69]. Thus, it is
likely that a percentage of steatosis and of related risk of incident
diabetes is due to overlapping NAFLD, particularly in genotype non-
3 HCV. The increased risk of prevalent and incident diabetes linked
with NAFLD is the most frequently documented in the literature.
In a systematic review and meta-analysis [83] of 21 prospective,
population-based studies in different ethnic groups, 1 log (×10)
higher alanine aminotransferase (ALT) values (in U/L) conferred a
hazard ratio (HR) of 1.85 (95% conﬁdence interval [CI] 1.57–2.18),
even if within the range of normal values. In the same meta-
analysis, the pooled relative risk for incident T2DM comparing
mild US-diagnosed NAFLD versus absence was 2.52 (CI 1.07–5.96).
Notably, the incidence rate of T2DM increases progressively accord-
ing to the ultrasonographic severity of NAFLD at baseline (normal:
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.0%, mild: 9.8%, moderate-to-severe: 17.8%, p < 0.001) after adjust-
ng for multiple confounders [84]. Only one study evaluated
ncident T2DM in adults with biopsy-proven NAFLD [85]. The
revalence of known T2DM was 8.5% at baseline. After a mean
eriod of 13.7 years, 78% of these patients developed either T2DM
58%) or impaired glucose tolerance (20%). Of note, patients with
ASH had an approximately three-fold higher risk of developing
2DM than those with simple steatosis. Importantly, it is conceiv-
ble that the T2DM risk attributable to NAFLD would persist even
fter complete viral eradication achieved by DAAs. Furthermore,
CV infection can also increase the risk of carotid atherosclero-
is [86]. An Italian study comparing 326 treatment-naive CHC (151
ithout steatosis) with 292 healthy subjects without steatosis and
85 age- and gender-matched NAFLD controls, found that both viral
oad and steatosis contribute to carotid atherosclerosis in CHC [87].
In conclusion, after successful HCV eradication by antiviral
herapy, both the cardiometabolic risk and the residual risk of pro-
ressive liver disease, particularly in the presence of persistent
AFLD, should not be overlooked and certainly deserve further
nvestigation.
. Impact of SVR on T2DM complications
What happens to CHC patients with T2DM obtaining SVR? This
ssue has important clinical and public health implications. In fact,
he vast majority of CHC patients have not yet been diagnosed and
ill not be treated in the near future despite the high efﬁcacy of
ovel antiviral treatments. Thus, the metabolic complications of
CV will probably represent a serious clinical and economic burden
or the next few decades; for this reason, it is of importance to
ssess whether HCV eradication in diabetic patients signiﬁcantly
ecreases T2DM-related complications.
The clinical impact of successful antiviral therapy on the
ong-term outcome of T2DM in diabetics with CHC remains largely
nknown. This is mainly due to the lack of prospective studies that
peciﬁcally address this important issue. According to a nationwide
opulation-based research conducted in Taiwan [88], antiviral
reatment for HCV infection is associated with improved renal
nd cardiovascular outcomes in diabetic patients. The reduction
ate of T2DM complications is impressive: patients given antiviral
reatment showed an 84% reduction in the risk of end-stage renal
isease (ESRD), 47% in that of ischaemic stroke and 36% in acute
oronary syndrome compared with the untreated cohort. However,
s correctly acknowledged by the authors, several methodological
imitations may  have affected the results and the conclusions of
he study. Patients with signiﬁcant comorbidity were excluded
rom the study, no data regarding SVR were reported and many
mportant variables regarding T2DM were lacking (length of dia-
etic history, BMI, smoking habit, alcohol intake, physical activity,
resence of steatohepatitis). Last but not least, data concerning
lycaemic control assessed by glycosylated haemoglobin were not
rovided. In diabetic patients, good glycaemic control prevents
he onset and progression of acute and long-term diabetes-related
omplications [89] and, conversely, poor metabolic control could
nhance or accelerate diabetes-related events. Further investi-
ations should be performed before the clinical message coming
rom this study can be accepted. The striking reduction in ESRD
bserved among the treated patients may  have other reasons and
echanisms, in particular the therapy-related disappearance of
ryoglobulinaemia and/or glomerulonephritis induced by HCV
90]. Moreover, the signiﬁcantly higher incidence of ESRD in
he untreated HCV cohort compared with the uninfected cohort
hows that diabetic microangiopathy was not the only reason for
enal failure. Cardiovascular events (ischaemic stroke and ACS)
eem signiﬁcantly reduced among treated patients compared with
ninfected or untreated patients, but only in those without Disease 48 (2016) 105–111 109
peripheral arterial disease. According to the authors, the presence
of peripheral arterial disease indicates a more diffuse process,
suggesting that the pathogenic role of HCV might be limited to the
early phase of atherosclerosis and that antiviral therapy cannot
reduce cardiovascular morbidity at an advanced stage. These
conclusions, however, as correctly underlined by the authors, need
to be moderated. First, no data regarding metabolic syndrome
(MS) among diabetic patients have been reported. The ultimate
importance of MS  is that it helps to identify individuals at high
risk of cardiovascular disease [91]: without this information, the
authors cannot rule out the possibility of an excess of patients
with MS  in the untreated/uninfected cohort. Second, the issue
of whether the reduction in cardiovascular events observed in
diabetic patients with CHC treated with IFN/RBV is due to a bene-
ﬁcial effect on T2DM or to the disappearance of systemic chronic
inﬂammation [92–99] remains to be addressed. Finally, whether
HCV is an independent risk factor for cardiovascular diseases
remains controversial. A recent review [100] reporting the results
of several cross-sectional and longitudinal studies suggests that
patients with CHC might show a high risk of cardiovascular dys-
function; the ﬁnal conclusion of another review [17] on the same
topic is more cautious, suggesting the need for further carefully
conducted, prospective cohort studies.
Another question pertains to the incidence of retinopathy
and/or peripheral neuropathy. In diabetic patients with CHC treated
with IFN/RBV [76], none of those who  obtained SVR developed
retinopathy and/or neuropathic symptoms, but the relatively small
number of patients does not allow deﬁnite conclusions to be drawn.
For this reason, a well-designed prospective study with a large
series of patients and a well-matched control group of diabetic
patients without CHC is needed.
6. Conclusions
Infection with HCV should be regarded as a systemic disease
associated with IR and T2DM. Curing HCV results in a reduced
incidence of T2DM, and an improvement of T2DM-related clini-
cal outcomes is possible in diabetic CHC patients who obtain SVR.
However, a deﬁnite verdict is not possible; for this reason, large
prospective cohort studies using appropriate stratiﬁcations are
urgently needed to evaluate the extent of such an amelioration.
The high therapeutic efﬁcacy of novel antivirals will ensure that a
large number of diabetic cirrhotic patients will achieve eradication;
this will enable us to understand the relative contribution of the
virus and of lifestyle (and genetics) on T2DM outcome. Meanwhile,
we can hypothesise that only early diagnosis and treatment of
HCV infection might be associated with regression of T2DM-related
clinical manifestations and complications, according to what is
known for other HCV-induced extrahepatic diseases. However, we
maintain that the clearance of HCV in patients predisposed to
T2DM should not discount the adequate management of IR through
lifestyle changes.
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